

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
BIFIDOBACTERIA.USPT.	227
BIFIDOBACTERIUM.USPT.	462
BIFIDOBACTERIUMS	0
BIFIDOBACTERIAS	0
(17 AND BIFIDOBACTERIA).USPT.	0
(L17 AND "BIFIDOBACTERIA").USPT.	0

US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Database:****Search:**  
 **Search History****DATE: Friday, October 18, 2002** [Printable Copy](#) [Create Case](#)

Set Name Query  
side by side

*DB=USPT; PLUR=YES; OP=OR*

		<u>Hit Count</u>	<u>Set Name</u>
			result set
<u>L19</u>	L17 and "Bifidobacteria"	0	<u>L19</u>
<u>L18</u>	L17 and "Bifidobacterium"	0	<u>L18</u>
<u>L17</u>	"producing lactoferrin" and "bacteria"	14	<u>L17</u>
<u>L16</u>	"secreting lactoferrin" and "bacteria"	0	<u>L16</u>
<u>L15</u>	"Bifidobacterium" and "lactoferrin"	16	<u>L15</u>
<u>L14</u>	"lactoferrin" and "Bifidobacteria transformant"	0	<u>L14</u>
<u>L13</u>	bacteria and l10	0	<u>L13</u>
<u>L12</u>	L10 and "Bifidobacteria"	0	<u>L12</u>
<u>L11</u>	L10 and "Bifidobacterium"	0	<u>L11</u>
<u>L10</u>	"bacteria producing lactoferrin"	0	<u>L10</u>
<u>L9</u>	"producing lactoferrin"	18	<u>L9</u>
<u>L8</u>	"forming lactoferrin"	0	<u>L8</u>
<u>L7</u>	"secreting lactoferrin"	0	<u>L7</u>
<u>L6</u>	L5 and "secreting lactoferrin"	0	<u>L6</u>
<u>L5</u>	"lactoferrin"	714	<u>L5</u>
<u>L4</u>	"Bifidobacterium" and "secreting lactoferrin"	0	<u>L4</u>
<u>L3</u>	"lactoferrin" and "bifidobacterium"	16	<u>L3</u>
<u>L2</u>	L1 and "lactoferrin"	0	<u>L2</u>
<u>L1</u>	4087559.bn.	1	<u>L1</u>

END OF SEARCH HISTORY

L23 ANSWER 1 OF 10 AGRICOLA  
AN 2001:80759 AGRICOLA  
DN IND23234393  
TI Protection from gastrointestinal diseases with the use of probiotics.  
AU Marteau, P.R.; Vrese, M. de.; Cellier, C.J.; Schrezenmeir, J.  
AV DNAL (389.8 J824)  
SO The American journal of clinical nutrition, Feb 2001. Vol. 73, No. 2S. p.  
430S-436S  
Publisher: Bethesda, Md. : American Society for Clinical Nutrition.  
CODEN: AJCNAC; ISSN: 0002-9165  
NTE Paper presented at the International Symposium on Probiotics and  
Prebiotics, June 11-12, 1998, Kiel, Germany.  
Includes references  
CY Maryland; United States  
DT Article  
FS U.S. Imprints not USDA, Experiment or Extension  
LA English

=> d 123 1-17

L23 ANSWER 1 OF 10 AGRICOLA  
AN 2001:80759 AGRICOLA  
DN IND23234393  
TI Protection from gastrointestinal diseases with the use of probiotics.  
AU Marteau, P.R.; Vrese, M. de.; Cellier, C.J.; Schrezenmeir, J.  
AV DNAL (389.8 J824)  
SO The American journal of clinical nutrition, Feb 2001. Vol. 73, No. 2S. p.  
430S-436S  
Publisher: Bethesda, Md. : American Society for Clinical Nutrition.  
CODEN: AJCNAC; ISSN: 0002-9165  
NTE Paper presented at the International Symposium on Probiotics and  
Prebiotics, June 11-12, 1998, Kiel, Germany.  
Includes references  
CY Maryland; United States  
DT Article  
FS U.S. Imprints not USDA, Experiment or Extension  
LA English

L23 ANSWER 2 OF 10 SCISEARCH COPYRIGHT 2002 ISI (R)  
AN 2000:278428 SCISEARCH  
GA The Genuine Article (R) Number: 300VK  
TI Lactose intolerance  
AU Vesa T H (Reprint); Marteau P; Korpela R  
CS VALIO LTD, RES & DEV, POB 30, FIN-00039 VALIO, FINLAND (Reprint); FDN  
NUTR RES, HELSINKI, FINLAND; LAENNECK HOSP, PARIS, FRANCE  
CYA FINLAND; FRANCE  
SO JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, (APR 2000) Vol. 19, No. 2,  
Supp. [S], pp. S165-S175.  
Publisher: AMER COLL NUTRITION, C/O HOSP. JOINT DIS. 301 E. 17TH ST., NEW  
YORK, NY 10003.  
ISSN: 0731-5724.  
DT General Review; Journal  
FS LIFE  
LA English  
REC Reference Count: 133  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L23 ANSWER 3 OF 10 USPATFULL  
AN 1999:110011 USPATFULL  
TI Stabilized biologically active compounds contained in coated  
microgranules which can be suspended in alimentary fluids  
IN Santus, Giancarlo, Milan, Italy  
PA Recordati S.A. Chemical and Pharmaceutical Company, Chiasso,  
Switzerland  
    (non-U.S. corporation)  
PI US 5952021 19990914  
AI US 1997-941730 19971001 (8)  
RLI Continuation of Ser. No. US 1995-458062, filed on 1 Jun 1995, now  
abandoned  
PRAI IT 1994-MI1231 19940614  
DT Utility  
FS Granted  
LN.CNT 735  
INCL INCLM: 426/034.000  
INCLS: 426/042.000; 426/051.000; 426/089.000; 426/580.000; 426/599.000  
NCL NCLM: 426/034.000  
NCLS: 426/042.000; 426/051.000; 426/089.000; 426/580.000; 426/599.000  
IC [6]  
    ICM: A23C009-12  
EXF 426/34; 426/89; 426/96; 426/580; 426/42; 426/43; 426/49; 426/51;  
426/52;  
    426/590; 426/599  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 4 OF 10 USPATFULL  
AN 96:45800 USPATFULL  
TI Food additive intended for human consumption and as animal feed and  
foodstuffs containing it  
IN Delespaul, Gilbert, Vendome, France  
    Dhoms, Philippe, Vendome, France  
    Raibaud, Pierre, Jouy-en-Josas, France  
    Szylit, Odette, Igny, France  
PA Fromageries Bel, Paris, France (non-U.S. corporation)  
PI US 5520936 19960528  
WO 9221246 19921210  
AI US 1994-157049 19940131 (8)  
    WO 1992-FR484 19920602  
    19940131 PCT 371 date  
    19940131 PCT 102(e) date  
PRAI FR 1991-6641 19910603  
DT Utility  
FS Granted  
LN.CNT 480  
INCL INCLM: 426/061.000  
INCLS: 424/093.100; 424/093.200; 424/093.300; 424/093.450; 424/093.460;  
099/452.000; 435/200.000; 435/252.100; 435/252.900  
NCL NCLM: 426/061.000  
NCLS: 099/452.000; 424/093.100; 424/093.200; 424/093.300; 424/093.450;  
424/093.460; 435/200.000; 435/252.100; 435/252.900  
IC [6]  
    ICM: A23C009-12  
    ICS: A01N063-00; C12N009-24; A01J011-00  
EXF 099/452; 424/93D; 424/93J; 424/93.1; 424/93.2; 424/93.3; 424/93.45;  
424/93.46; 435/200; 435/252.1; 435/252.9; 426/61

L23 ANSWER 5 OF 10 CABA COPYRIGHT 2002 CABI  
AN 96:133073 CABA  
DN 960404131  
TI Improvement of lactose digestion in humans by ingestion of unfermented  
milk containing **Bifidobacterium longum**  
AU Jiang TiaNan; Mustapha, A.; Savaiano, D. A.; Jiang, T. N.  
CS Department of Food Science and Nutrition, University of Minnesota, St.  
Paul 55108, Minnesota, USA.

SO Journal of Dairy Science, (1996) Vol. 79, No. 5, pp. 750-757. 28 ref.  
ISSN: 0022-0302  
DT Journal  
LA English

L23 ANSWER 6 OF 10 AGRICOLA DUPLICATE 1  
AN 1998:29783 AGRICOLA  
DN IND20800043  
TI Digestion and tolerance of lactose from yoghurt and different semi-solid  
fermented dairy products containing Lactobacillus acidophilus and  
bifidobacteria in lactose malabsorbers--Is bacterial lactase important?  
AU Vesa, T.H.; Marteau, P.; Zidi, S.; Briet, F.; Pochart, P.; Rambaud, J.C.  
AV DNAL (QP141.A1J68)  
SO European journal of clinical nutrition, Nov 1996. Vol. 50, No. 11. p.  
730-733  
Publisher: Basingstoke : Stockton Press.  
CODEN: EJCNEQ; ISSN: 0954-3007  
NTE Includes references  
CY United Kingdom  
DT Article  
FS Non-U.S. Imprint other than FAO  
LA English

L23 ANSWER 7 OF 10 JICST-EPlus COPYRIGHT 2002 JST  
AN 960017524 JICST-EPlus  
TI Intestinal adaptation to long-term lactose feeding in teh rat.  
AU FUKUDA SHINSAKU; KAWAMURA KAZUKO; TAKAHASHI TOSHIYUKI; TONO HIROSHI; BABA  
TAKIO; YOSHIDA YUTAKA  
CS Hirosaki Univ.  
SO Shoka to Kyushu (Digestion & Absorption), (1995) vol. 18, no. 1, pp.  
103-106. Journal Code: X0025A (Fig. 4, Ref. 7)  
ISSN: 0389-3626  
CY Japan  
DT Journal; Article  
LA Japanese  
STA New

L23 ANSWER 8 OF 10 CABA COPYRIGHT 2002 CABI DUPLICATE 2  
AN 95:2251 CABA  
DN 940404885  
TI Dairy products and intestinal flora  
AU Rambaud, J. C.; Bouhnik, Y.; Marteau, P.; Serrano Rios, M. [EDITOR];  
Sastre, A. [EDITOR]; Perez Juez, M. A. [EDITOR]; Estrala, A. [EDITOR];  
Sebastian, C. de [EDITOR]  
CS Service de Gastroenterologie et Unite INSERM U 290, Hopital Saint-Lazare,  
Paris, France.  
SO (1994) pp. 389-399. 41 ref.  
Publisher: A. A. Balkema. Rotterdam  
Meeting Info.: Dairy products in human health and nutrition. Proceedings  
of the 1st World Congress, Madrid, Spain, 7-10 June 1993.  
ISBN: 90-5410-359-0  
CY Netherlands Antilles  
DT Conference Article  
LA English

L23 ANSWER 9 OF 10 BIOSIS COPYRIGHT 2002 BIOSIS DUPLICATE 3  
AN 1992:71289 BIOSIS  
DN BA93:39744  
TI STRAINS AND SPECIES OF LACTIC ACID BACTERIA IN FERMENTED MILKS YOGURTS  
EFFECT ON IN-VIVO LACTOSE DIGESTION.  
AU MARTINI M C; LEREBOURS E C; LIN W-J; HARLANDER S K; BERRADA N M; ANTOINE  
J  
M; SAVAIANO D A  
CS DEP. OF FOOD SCI. AND NUTRITION, UNIV. MINNESOTA, ST. PAUL, MINN. 55108.  
SO AM J CLIN NUTR, (1991) 54 (6), 1041-1046.  
CODEN: AJCNAC. ISSN: 0002-9165.

FS BA; OLD  
LA English

L23 ANSWER 10 OF 10 BIOBUSINESS COPYRIGHT 2002 BIOSISDUPLICATE 4  
AN 90:41925 BIOBUSINESS  
DN 0279539  
TI Lactose and galactose contents in various yogurts and fermented milks.  
AU DESMAISON A-M; PASCAUD H; TIXIER M  
CS FAC. PHARMACIE, LAB. CHIM. BIOL., 2 RUE DU DOCTEUR MARCLAND, 87025  
LIMOGES  
CEDEX, FR.  
SO SCIENCES DES ALIMENTS, (1990) VOL.10, NO.2, P.357-368.  
FS NONUNIQUE  
LA FRENCH

=> d 1 ab

L23 ANSWER 1 OF 10 AGRICOLA  
AB Probiotics are nonpathogenic microorganisms that, when ingested, exert a positive influence on the health or physiology of the host. They can influence intestinal physiology either directly or indirectly through modulation of the endogenous ecosystem or immune system. The results that have been shown with a sufficient level of proof to enable probiotics to be used as treatments for gastrointestinal disturbances are 1) the good tolerance of yogurt compared with milk in subjects with primary or secondary lactose maldigestion, 2) the use of *Saccharomyces boulardii* and *Enterococcus faecium* SF 68 to prevent or shorten the duration of antibiotic-associated diarrhea, 3) the use of *S. boulardii* to prevent further recurrence of *Clostridium difficile*-associated diarrhea, and 4) the use of fermented milks containing *Lactobacillus rhamnosus* GG to shorten the duration of diarrhea in infants with rotavirus enteritis (and probably also in gastroenteritis of other causes). Effects that are otherwise suggested for diverse probiotics include alleviation of diarrhea of miscellaneous causes; prophylaxis of gastrointestinal infections, which includes traveler's diarrhea; and immunomodulation. Trials of gastrointestinal diseases that involve the ecosystem are currently being performed, eg, *Helicobacter pylori* infections, inflammatory bowel disease, and colon cancer.

=> d hit 1

L23 ANSWER 1 OF 10 AGRICOLA  
CT **bifidobacterium**; colorectal cancer; diarrhea; diet treatment; disease prevention; food products; gastroenteritis; gastrointestinal diseases; health promotion; infections; inflammation; ingredients; intestinal microorganisms; irritable colon; **lactase deficiency**; *lactobacillus*; lactose intolerance; literature reviews; malabsorption; microbial flora; pathogens; probiotics; supplements

=> d 1

L23 ANSWER 1 OF 10 AGRICOLA  
AN 2001:80759 AGRICOLA  
DN IND23234393  
TI Protection from gastrointestinal diseases with the use of probiotics.  
AU Marteau, P.R.; Vreese, M. de.; Cellier, C.J.; Schrezenmeir, J.

AV DNAL (389.8 J824)  
SO The American journal of clinical nutrition, Feb 2001. Vol. 73, No. 2S. p.  
430S-436S  
Publisher: Bethesda, Md. : American Society for Clinical Nutrition.  
CODEN: AJCNAC; ISSN: 0002-9165  
NTE Paper presented at the International Symposium on Probiotics and  
Prebiotics, June 11-12, 1998, Kiel, Germany.  
Includes references  
CY Maryland; United States  
DT Article  
FS U.S. Imprints not USDA, Experiment or Extension  
LA English

=> d 1 kwic

L23 ANSWER 1 OF 10 AGRICOLA  
CT **bifidobacterium**; colorectal cancer; diarrhea; diet treatment;  
disease prevention; food products; gastroenteritis; gastrointestinal  
diseases; health promotion; infections; inflammation; ingredients;  
intestinal microorganisms; irritable colon; **lactase**  
**deficiency**; lactobacillus; lactose intolerance; literature  
reviews; malabsorption; microbial flora; pathogens; probiotics;  
supplements

L44 ANSWER 2 OF 2 SCISEARCH COPYRIGHT 2002 ISI (R)

AB The effect of immobilized bifidobacteria on **growth** and **siderophore** production of pathogenic strains of *E. coli* was investigated. **Bifidobacterium** sp. No. 904 significantly decreased numbers of two invasive avian *E. coli* strains during coculture cultivation. In addition significant decreasing of **siderophore** (aerobactin) level in *E. coli* was found.

L44 ANSWER 2 OF 2 SCISEARCH COPYRIGHT 2002 ISI (R)  
AN 93:76436 SCISEARCH  
GA The Genuine Article (R) Number: KJ641  
TI INTERACTIONS OF BIFIDOBACTERIA WITH PATHOGENIC ESCHERICHIA-COLI  
AU KMET V (Reprint); CIZMAROVA J; KMETOVA M  
CS SLOVAK ACAD SCI, INST ANIM PHYSIOL, DUKELSKYCH HRDINOV 1B, CS-04001  
KOSICE, CZECHOSLOVAKIA (Reprint)  
CYA CZECHOSLOVAKIA  
SO BIOLOGIA, (1992) Vol. 47, No. 9, pp. 767-769.  
ISSN: 0006-3088.  
DT Article; Journal  
FS AGRI  
LA ENGLISH  
REC No References Keyed  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

> d 1-8

L47 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2002 ACS  
AN 2001:932983 CAPLUS  
TI Bifidobacteria and siderophores produced thereby and methods of use  
IN O'Sullivan, Daniel J.  
PA Regents of the University of Minnesota, USA  
SO PCT Int. Appl.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001098516	A2	20011227	WO 2001-US41036	20010619
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-212273	A1	20000619		

L47 ANSWER 2 OF 8 USPATFULL  
AN 2000:77340 USPATFULL  
TI Methods for improving the activity of .delta.-endotoxins against insect  
pests  
IN English, Leigh H., Churchville, PA, United States  
Brussock, Susan M., New Hope, PA, United States  
Malvar, Thomas M., St. Louis, MO, United States  
Bryson, James W., Langhorne, PA, United States  
Kulesza, Caroline A., Charlottesville, VA, United States  
Walters, Frederick S., Beaver Falls, PA, United States  
Slatin, Stephen L., Fair Lawn, NJ, United States  
Von Tersch, Michael A., Erving Township, NJ, United States  
PA Ecogen, Inc., Langhorne, PA, United States (U.S. corporation)  
PI US 6077824 20000620  
AI US 1997-993775 19971218 (8)  
DT Utility  
FS Granted  
LN.CNT 48511  
INCL INCLM: 514/012.000  
INCLS: 435/069.100; 514/002.000; 530/350.000; 530/402.000  
NCL NCLM: 514/012.000  
NCLS: 435/069.100; 514/002.000; 530/350.000; 530/402.000  
IC [7]  
ICM: A61K038-16  
ICS: C07K014-325; C12P021-02  
EXF 530/350; 530/40.2; 435/69.1; 435/172.3; 514/2; 514/12  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 3 OF 8 USPATFULL  
AN 2000:61413 USPATFULL  
TI Polypeptide compositions toxic to coleopteran insects  
IN English, Leigh H., Churchville, PA, United States  
Brussock, Susan M., New Hope, PA, United States

Malvar, Thomas M., St. Louis, MO, United States  
Bryson, James W., Langhorne, PA, United States  
Kulesza, Caroline A., Charlottesville, VA, United States  
Walters, Frederick S., Beaver Falls, PA, United States  
Slatin, Stephen L., Fair Lawn, NJ, United States  
Von Tersch, Michael A., Ewing Township, NJ, United States  
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
PI US 6063597 20000516  
AI US 1997-993170 19971218 (8)  
DT Utility  
FS Granted  
LN.CNT 17128  
INCL INCLM: 435/069.100  
INCLS: 514/012.000; 530/350.000; 536/023.710  
NCL NCLM: 435/069.100  
NCLS: 514/012.000; 530/350.000; 536/023.710  
IC [7]  
ICM: C12P021-06  
ICS: A61K038-00; C07K001-00; C07H021-04  
EXF 424/93; 424/832; 435/252.31; 435/252.3; 435/320.1; 536/23.71; 536/24.32  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 4 OF 8 USPATFULL  
AN 2000:57888 USPATFULL  
TI Nucleic acid segments encoding modified bacillus thuringiensis  
coleopteran-toxic crystal proteins  
IN English, Leigh H., Churchville, PA, United States  
Brussock, Susan M., New Hope, PA, United States  
Malvar, Thomas M., St. Louis, MO, United States  
Bryson, James W., Langhorne, PA, United States  
Kulesza, Caroline A., Charlottesville, VA, United States  
Walters, Frederick S., Beaver Falls, PA, United States  
Slatin, Stephen L., Fair Lawn, NJ, United States  
Von Tersch, Michael A., Ewing Township, NJ, United States  
Romano, Charles, Ballwin, MO, United States  
PA Ecogen, Inc., Langhorn, PA, United States (U.S. corporation)  
Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
PI US 6060594 20000509  
AI US 1997-993722 19971218 (8)  
DT Utility  
FS Granted  
LN.CNT 16988  
INCL INCLM: 536/023.710  
INCLS: 435/320.100; 435/440.000  
NCL NCLM: 536/023.710  
NCLS: 435/320.100; 435/440.000  
IC [7]  
ICM: C12N015-32  
ICS: C12N015-82  
EXF 435/320.1; 435/440; 536/23.71; 536/24.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 5 OF 8 USPATFULL  
AN 2000:15789 USPATFULL  
TI Insect-resistant transgenic plants  
IN English, Leigh H., Churchville, PA, United States  
Brussock, Susan M., New Hope, PA, United States  
Malvar, Thomas M., St. Louis, MO, United States  
Bryson, James W., Langhorne, PA, United States  
Kulesza, Caroline A., Charlottesville, VA, United States  
Walters, Frederick S., Beaver Falls, PA, United States  
Slatin, Stephen L., Fair Lawn, NJ, United States  
Von Tersch, Michael A., Ewing Township, NJ, United States  
Romano, Charles, Wildwood, MO, United States  
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
Ecogen, Inc., Langhorne, PA, United States (U.S. corporation)

PI US 6023013 20000208  
AI US 1997-996441 19971218 (8)  
DT Utility  
FS Granted  
LN.CNT 16867  
INCL INCLM: 800/302.000  
INCLS: 435/252.300; 435/419.000; 800/279.000  
NCL NCLM: 800/302.000  
NCLS: 435/252.300; 435/419.000; 800/279.000  
IC [6]  
ICM: A01H005-00  
ICS: A01H005-10; C12N001-21; C12N005-14  
EXF 536/23.71; 436/320.1; 436/69.1; 436/235.1; 436/243; 436/252.3;  
436/252.2; 436/252.31; 436/252.33; 436/252.34; 436/419; 436/411;  
436/412; 436/414; 436/415; 436/416; 436/417; 436/418; 436/468; 436/469;  
436/470; 436/440; 800/279; 800/302  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 6 OF 8 DRUGU COPYRIGHT 2002 DERWENT INFORMATION LTD  
AN 1999-01362 DRUGU M  
TI Mechanism of inhibition of tannic acid and related compounds on the  
growth of intestinal bacteria.  
AU Chung K T; Lu Z; Chou M W  
CS Univ.Memphis  
LO Memphis, Tenn.; Jefferson, Ariz., USA  
SO Food Chem.Toxicol. (36, No. 12, 1053-60, 1998) 3 Fig. 2 Tab. 38 Ref.  
CODEN: FCTOD7 ISSN: 0278-6915  
AV Department of Microbiology and Molecular Cell Sciences, The University  
of  
Memphis, Memphis, TN 38152, U.S.A.  
LA English  
DT Journal  
FA AB; LA; CT  
FS Literature

L47 ANSWER 7 OF 8 BIOSIS COPYRIGHT 2002 BIOSIS DUPLICATE 1  
AN 1993:208519 BIOSIS  
DN PREV199395109744  
TI Interactions of bifidobacteria with pathogenic Escherichia coli.  
AU Kmet, Vladimir (1); Cizmarova, Judita (1); Kmetova, Marta  
CS (1) Inst. Anim. Physiol., Slovak Acad. Sci., Dukelskych hrdinov 1 B,  
CS-040 01 Kosice, Czechoslovakia  
SO Biologia (Bratislava), (1992) Vol. 47, No. 9, pp. 767-769.  
ISSN: 0006-3088.  
DT Article  
LA English  
SL English; Slovak

L47 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2  
AN 1986:221796 CAPLUS  
DN 104:221796  
TI Iron uptake by **Bifidobacterium** bifidum var. pennsylvanicus: the  
effect of sulphydryl reagents and metal chelators  
AU Topouzian, Nancy; Bezkorovainy, Anatoly  
CS Dep. Biochem., Rush Presbyterian-St Luke's Med. Cent., Chicago, IL,  
60612,  
USA  
SO IRCS Med. Sci. (1986), 14(3), 275-6  
CODEN: IMSCE2  
DT Journal  
LA English

L47 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2  
AN 1986:221796 CAPLUS  
DN 104:221796  
TI Iron uptake by **Bifidobacterium** bifidum var. pennsylvanicus: the effect of sulfhydryl reagents and metal chelators  
AU Topouzian, Nancy; Bezkorovainy, Anatoly  
CS Dep. Biochem., Rush Presbyterian-St Luke's Med. Cent., Chicago, IL, 60612,  
USA  
SO IRCS Med. Sci. (1986), 14(3), 275-6  
CODEN: IMSCE2  
DT Journal  
LA English

=> d 8 ab

L47 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2  
AB Fe<sup>2+</sup> uptake by *B. bifidum* pennsylvanicus was examed. by using <sup>59</sup>Fe<sup>2+</sup> as a tracer. Transport was inhibited by sulfhydryl-specific inhibitors (trinitrobenzene sulfonic acid, p-chloromercuribenzoate, and iodoacetate). Thus, sulfhydryl groups are crucial for the transport mechanism. Fe chelators, including **siderophore**, ionophore, and lipophilic types, also inhibited uptake of Fe<sup>2+</sup>. This suggests either that a very specific Fe carrier is required or that Fe<sup>2+</sup> is taken up in its free form and chelation presents a barrier to movement into the cell.

L56 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2002 BIOSIS  
AN 1993:208519 BIOSIS  
DN PREV199395109744  
TI Interactions of bifidobacteria with pathogenic Escherichia coli.  
AU Kmet, Vladimir (1); Cizmarova, Judita (1); Kmetova, Marta  
CS (1) Inst. Anim. Physiol., Slovak Acad. Sci., Dukelskych hrdinov 1 B,  
CS-040 01 Kosice, Czech-Slovakia  
SO Biologia (Bratislava), (1992) Vol. 47, No. 9, pp. 767-769.  
ISSN: 0006-3088.

DT Article  
LA English  
SL English; Slovak

L56 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS

AN 2001:932983 CAPLUS  
TI Bifidobacteria and siderophores produced thereby and methods of use  
IN O'Sullivan, Daniel J.  
PA Regents of the University of Minnesota, USA  
SO PCT Int. Appl.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001098516	A2	20011227	WO 2001-US41036	20010619
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2000-212273 A1 20000619

L56 ANSWER 3 OF 3 DRUGU COPYRIGHT 2002 DERWENT INFORMATION LTD

AN 1999-01362 DRUGU M  
TI Mechanism of inhibition of tannic acid and related compounds on the  
growth of intestinal bacteria.  
AU Chung K T; Lu Z; Chou M W  
CS Univ. Memphis  
LO Memphis, Tenn.; Jefferson, Ariz., USA  
SO Food Chem. Toxicol. (36, No. 12, 1053-60, 1998) 3 Fig. 2 Tab. 38 Ref.  
SO CODEN: FCTOD7 ISSN: 0278-6915  
AV Department of Microbiology and Molecular Cell Sciences, The University  
of

Memphis, Memphis, TN 38152, U.S.A.

LA English  
DT Journal  
FA AB; LA; CT  
FS Literature

L56

3 L55 AND BIFIDOBACTERIUM(P) SIDEROPHORE

=> d 1-3

L56 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2002 BIOSIS  
AN 1993:208519 BIOSIS  
DN PREV199395109744  
TI Interactions of bifidobacteria with pathogenic Escherichia coli.  
AU Kmet, Vladimir (1); Cizmarova, Judita (1); Kmetova, Marta  
CS (1) Inst. Anim. Physiol., Slovak Acad. Sci., Dukelskych hrdinov 1 B,  
CS-040 01 Kosice, Czechoslovakia  
SO Biologia (Bratislava), (1992) Vol. 47, No. 9, pp. 767-769.  
ISSN: 0006-3088.  
DT Article  
LA English  
SL English; Slovak

L56 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS  
AN 2001:932983 CAPLUS  
TI Bifidobacteria and siderophores produced thereby and methods of use  
IN O'Sullivan, Daniel J.  
PA Regents of the University of Minnesota, USA  
SO PCT Int. Appl.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001098516	A2	20011227	WO 2001-US41036	20010619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2000-212273	A1	20000619		

L56 ANSWER 3 OF 3 DRUGU COPYRIGHT 2002 DERWENT INFORMATION LTD  
AN 1999-01362 DRUGU M  
TI Mechanism of inhibition of tannic acid and related compounds on the  
growth of intestinal bacteria.  
AU Chung K T; Lu Z; Chou M W  
CS Univ. Memphis  
LO Memphis, Tenn.; Jefferson, Ariz., USA  
SO Food Chem. Toxicol. (36, No. 12, 1053-60, 1998) 3 Fig. 2 Tab. 38 Ref.  
CODEN: FCTOD7 ISSN: 0278-6915  
AV Department of Microbiology and Molecular Cell Sciences, The University  
of  
of  
Memphis, Memphis, TN 38152, U.S.A.  
LA English  
DT Journal  
FA AB; LA; CT  
FS Literature

6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS  
AN 1986:221796 CAPLUS  
DN 104:221796  
TI Iron uptake by **Bifidobacterium** bifidum var. pennsylvanicus: the effect of sulfhydryl reagents and metal chelators  
AU Topouzian, Nancy; Bezkorovainy, Anatoly  
CS Dep. Biochem., Rush Presbyterian-St Luke's Med. Cent., Chicago, IL, 60612,  
USA  
SO IRCS Med. Sci. (1986), 14(3), 275-6  
CODEN: IMSCE2  
DT Journal  
LA English

=> d 2 ab

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS  
AB Fe<sup>2+</sup> uptake by *B. bifidum pennsylvanicus* was examined by using <sup>59</sup>Fe<sup>2+</sup> as a tracer. Transport was inhibited by sulfhydryl-specific inhibitors (trinitrobenzene sulfonic acid, p-chloromercuribenzoate, and iodoacetate). Thus, sulfhydryl groups are crucial for the transport mechanism. Fe chelators, including **siderophore**, ionophore, and lipophilic types, also inhibited uptake of Fe<sup>2+</sup>. This suggests either that a very specific Fe carrier is required or that Fe<sup>2+</sup> is taken up in its free form and chelation presents a barrier to movement into the cell.

=> d kwic 2

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS  
TI Iron uptake by **Bifidobacterium** bifidum var. pennsylvanicus: the effect of sulfhydryl reagents and metal chelators  
AB . . . sulfhydryl-specific inhibitors (trinitrobenzene sulfonic acid, p-chloromercuribenzoate, and iodoacetate). Thus, sulfhydryl groups are crucial for the transport mechanism. Fe chelators, including **siderophore**, ionophore, and lipophilic types, also inhibited uptake of Fe<sup>2+</sup>. This suggests either that a very specific Fe carrier is required. . .  
ST **Bifidobacterium** iron transport  
IT Mercapto group  
(iron transport by **Bifidobacterium** bifidum pennsylvanicus in relation to)  
IT Chelating agents  
(iron transport by **Bifidobacterium** bifidum pennsylvanicus response to)  
IT **Bifidobacterium** bifidum pennsylvanicus  
(iron transport by, sulfhydryl reagents and metal chelators effect on)  
IT Biological transport  
(absorption, of iron, by **Bifidobacterium** bifidum pennsylvanicus, sulfhydryl reagents and metal chelators effect on)  
IT 7439-89-6, biological studies  
RL: BIOL (Biological study)  
(transport of, by **Bifidobacterium** bifidum pennsylvanicus, sulfhydryl reagents and metal chelators effect on)

=>

L9 ANSWER 2 OF 2 SCISEARCH COPYRIGHT 2002 ISI (R)  
AN 93:76436 SCISEARCH  
GA The Genuine Article (R) Number: KJ641  
TI INTERACTIONS OF BIFIDOBACTERIA WITH PATHOGENIC ESCHERICHIA-COLI  
AU KMET V (Reprint); CIZMAROVA J; KMETOVA M  
CS SLOVAK ACAD SCI, INST ANIM PHYSIOL, DUKELSKYCH HRDINOV 1B, CS-04001  
KOSICE, CZECHOSLOVAKIA (Reprint)  
CYA CZECHOSLOVAKIA  
SO BIOLOGIA, (1992) Vol. 47, No. 9, pp. 767-769.  
ISSN: 0006-3088.  
DT Article; Journal  
FS AGRI  
LA ENGLISH  
REC No References Keyed  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

=> d 2 hit

L9 ANSWER 2 OF 2 SCISEARCH COPYRIGHT 2002 ISI (R)  
AB The effect of immobilized bifidobacteria on **growth** and  
**siderophore** production of pathogenic strains of *E. coli* was  
investigated. **Bifidobacterium** sp. No. 904 significantly  
decreased numbers of two invasive avian *E. coli* strains during coculture  
cultivation. In addition significant decreasing of **siderophore**  
(aerobactin) level in *E. coli* was found.  
ST Author Keywords: **BIFIDOBACTERIUM; IRON INTAKE**  
ACTIVITY; SIDEROPHORES; AEROBACTIN; ESCHERICHIA-COLI

=> s 19 and *bifidobacterium* secret?

L10 O L9 AND *BIFIDOBACTERIUM* SECRET?

=> s 19 and secret?

L11 O L9 AND SECRET?

102/103  
class 4-15 ; 16-22, 27, 29

> d 18

L12 ANSWER 18 OF 54 CAPLUS COPYRIGHT 2002 ACS  
AN 1997:698332 CAPLUS  
DN 127:343663  
TI Iron requirement and siderophore production in Rhizobium ciceri during growth on an iron-deficient medium  
AU Berraho, El.; Lesueur, D.; Diem, H. G.; Sasson, A.  
CS Laboratoire de Microbiologie, Universite Mohammed V, Rabat, Morocco  
SO World Journal of Microbiology & Biotechnology (1997), 13(5), 501-510  
CODEN: WJMBEY; ISSN: 0959-3993  
PB Rapid Science Publishers  
DT Journal  
LA English

=> d 18 ab

L12 ANSWER 18 OF 54 CAPLUS COPYRIGHT 2002 ACS  
AB Under conditions of Fe limitation many rhizospheric **bacteria** produce **siderophores**, Fe<sup>3+</sup>-specific ligands, which may enhance plant growth by increasing the availability of Fe near the roots. Thirty-five strains of R. ciceri, specific to chickpea (*Cicer arietinum* L.), were screened for their ability to grow on Fe-deficient medium and to produce **siderophores**. Max. growth of all strains previously depleted in Fe was obtained in medium contg. 5-10 .mu.M Fe<sup>3+</sup>. When Fe limitation was achieved by the addn. of 2,2-bipyridyl or EDDHA [ethylene diamine di(o-hydroxyphenyl)acetic acid] to the medium, only 2 strains were able to scavenge Fe and grow. **Siderophore** prodn. by these 2 strains was detected by the Chrome Azurol S assay (CAS), a universal test for **siderophores**. No hydroxamate-type **siderophores** were detected in the supernatants of Rhizobium ciceri cultures. However, some strains secreted salicylic acid and 2,3-dihydroxybenzoic acid as phenolate-type **siderophores**. Addn. of Fe<sup>3+</sup> to the culture medium increased growth yield significantly but depressed the prodn. of **siderophores**. Although these compds. are produced in response to Fe deficiency, nutritive components of the culture medium significantly affected their prodn. It seems that Cu<sup>2+</sup>, Mo<sup>6+</sup>, and Mn<sup>2+</sup> bound competitively with Fe to **siderophores**, resulting in a 34-100% increase in prodn.

=>

> d 10

L12 ANSWER 10 OF 54 CAPLUS COPYRIGHT 2002 ACS  
AN 1999:722846 CAPLUS  
DN 131:333001  
TI Enhancing the anti-corrosion effects of biofilms by introducing bacteria which secrete antimicrobials capable of inhibiting sulfate-reducing bacteria  
IN Wood, Thomas K.; Jayaraman, Arul; Earthman, James C.  
PA The Regents of the University of California, USA  
SO PCT Int. Appl., 84 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9956553	A1	19991111	WO 1999-US9675	19990503
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9938785	A1	19991123	AU 1999-38785	19990503
EP 1011331	A1	20000628	EP 1999-921627	19990503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002511105	T2	20020409	JP 1999-555720	19990503
NO 9906555	A	20000306	NO 1999-6555	19991229
FI 2000000010	A	20000303	FI 2000-10	20000104
PRAI US 1998-74037	A	19980506		
US 1999-282277	A	19990331		
WO 1999-US9675	W	19990503		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 10 ab

L12 ANSWER 10 OF 54 CAPLUS COPYRIGHT 2002 ACS  
AB The invention provides a system for inhibiting corrosion, comprising a corrosion or degrdn. sensitive material (metals, concrete, or cement) having a biofilm on its surface, wherein the biofilm includes a bacterium which secretes a chem. compn. in an amt. sufficient to inhibit the growth of sulfate-reducing bacteria on the material. The bacterium included in the biofilm is preferably an aerobe, particularly of the genus *Pseudomonas* or the genus *Bacillus*. The compn. secreted can be an antibiotic, such as gramicidin S, indolicidin, polymyxin, or bactenecin; a polyamino acid, such as polyaspartate or polyglutamate; or it can be a siderophore.

=>